Luxana Biotech is a preclinical antisense oligonucleotide (ASO) development company based on proprietary nucleic acids with unique cross-linking structures. We have created the LuxiAP™ ASO drug discovery platform for the central nervous system and ophthalmic fields. The company has collaborative research agreements with multiple pharmaceutical companies and maintains its own ASO pipeline. We are seeking to expand partnership opportunities not only for collaborative research with pharmaceutical companies but also for joint development utilizing our proprietary pipeline.
ルクサナバイオテク株式会社と住商ファーマインターナショナル株式会社によるルクサナバイオテクの人工修飾核酸アミダイトの製造販売に係るライセンスの契約を締結しましたのでお知らせします。 [画像: https://p...
[画像: https://prtimes.jp/i/49692/13/resize/d49692-13-40a38d37771416c2edb6-0.png ] 製薬会社・化学会社と協働し、有望な人工核酸を活用した核酸医薬創薬を目指すルクサナバイオテク株式会社（本社：大阪府...
[画像: https://prtimes.jp/i/49692/9/resize/d49692-9-51a392b4d1239b861316-0.png ]   ルクサナバイオテク株式会社（代表取締役社長CEO：佐藤秀昭、本社：大阪府吹田市、以下「ルクサナバイ...
[画像: https://prtimes.jp/i/49692/8/resize/d49692-8-540686c9ee246c06666b-0.png ] ルクサナバイオテク株式会社（代表取締役社長：佐藤秀昭、本社：大阪府吹田市、以下「ルクサナバイオテク」）は、武田薬...
  [画像: https://prtimes.jp/i/49692/6/resize/d49692-6-73d0358b1bc375d57266-0.png ] 新規人工核酸を駆使し有効性と安全性の高い核酸医薬品を開発するルクサナバイオテク株式会社（本社：大阪府吹...
[画像: https://prtimes.jp/i/49692/5/resize/d49692-5-fdbb342ebd6451f9a275-0.png ] ルクサナバイオテク株式会社（代表取締役 佐藤 秀昭、本社：大阪府、以下「ルクサナバイオテク」）は、2018 年 12 月に Al...
[画像: https://prtimes.jp/i/49692/4/resize/d49692-4-254796-0.png ] ルクサナバイオテク株式会社（本社：大阪府吹田市、代表取締役社長：佐藤 秀昭、以下「ルクサナバイオテク」）は、大日本住友製薬株...
[画像: https://prtimes.jp/i/49692/3/resize/d49692-3-360475-0.png ]     安全性と有効性の高い新規核酸医薬品を開発するルクサナバイオテク株式会社（本社：大阪府吹田市、代表取締役社長...
ルクサナバイオテク株式会社（本社：大阪府吹田市、代表取締役社長：佐藤 秀昭、以下「ルクサナバイオテク」）と学校法人愛知医科大学（本学：愛知県長久手市、以下「愛知医科大」）は、国立研究開発法人日本...
The University of Osaka–developed “next-generation microfluidic PCR technology” is leveraged to deliver a rapid and easy-to-use gut microbiome testing service, and to operate a community platform business that connects people with digestive concerns with companies offering products to support gut health. We also provide contract testing services for gut microbiome analysis.
As a drug discovery venture originating from Kyoto University, we are developing RN-501, a novel boron-containing drug for boron-neutron capture therapy (BNCT), a next-generation cancer radiation therapy targeting intractable cancers. Through proprietary boron carbide nanoparticle technology and polyglycerol modification, RN-501 achieves high tumor selectivity and accumulation, along with potent cancer-killing and immune-activating effects with a single intravenous administration, overcoming the limitations of existing drugs. As Japan's first and the world's first nano-BNCT drug, we aim for early societal implementation.
Our mission is to safeguard the health of people worldwide. We are an Osaka University-spun-off healthcare startup in the healthcare/preventive medicine field, developing and providing the “Blood Vessel Beauty” scope—which observes capillary blood flow from the fingertip without blood sampling—along with the capillary image analysis software ‘CAS’ and the cloud-based evaluation system “CAS-Rating.” We research the relationship between capillary data and health/disease risks, aiming to implement new health indicators and preventive medical services in society.
A startup overcoming challenges in exosome purification with proprietary high-purity, high-yield technology, offering end-to-end support from research to manufacturing. It accelerates practical applications in drug discovery, contributing to a new foundation for pharmaceutical development and driving medical innovation.